Related Experiment Video

Updated: Aug 8, 2025

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers
10:49

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers

Published on: September 26, 2019

5.7K

Addressing Transcriptional Dysregulation in Cancer through CDK9 Inhibition

Mohammed A Toure1,2,3, Angela N Koehler1,2,3

  • 1Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, United States.

Biochemistry
|February 28, 2023
PubMed

Insights

Targeting Cyclin-dependent kinase 9 (CDK9) offers a strategy to disrupt cancer's reliance on specific gene expression programs. New selective CDK9 inhibitors show promise for treating cancers, overcoming challenges of earlier drugs.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cancers often depend on specific transcriptional programs, creating a vulnerability.
  • Cyclin-dependent kinase 9 (CDK9) regulates RNA polymerase II (RNA Pol II) activity, making it a potential therapeutic target.
  • Previous attempts to inhibit CDK9 were hampered by severe toxicity and off-target effects from non-selective inhibitors.

Purpose of the Study:

  • To explore the therapeutic potential of targeting CDK9 in cancer treatment.
  • To address the unmet clinical need in cancers driven by aberrant transcriptional programs.
  • To highlight the promise of newly developed selective CDK9 inhibitors.

Main Methods:

  • Review of CDK9's role in transcriptional regulation.
  • Analysis of challenges associated with CDK9 inhibition.
  • Evaluation of emerging selective CDK9 inhibitor candidates.

Main Results:

  • CDK9 is crucial for RNA Pol II pause-release, impacting cancer gene expression.
  • Non-selective CDK inhibition leads to significant toxicity and polypharmacology.
  • A new generation of selective CDK9 inhibitors is advancing in clinical trials.

Conclusions:

  • Targeting CDK9 is a viable strategy for cancers with high unmet need.
  • Selective CDK9 inhibition offers a promising therapeutic avenue, mitigating toxicity concerns.
  • Further clinical evaluation of selective CDK9 inhibitors is warranted.

More Related Videos

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers03:37

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Published on: March 1, 2024

827
Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter11:32

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

7.0K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.6K
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K